trastuzumab biobetter (ViroMed/Reyon/Eureka)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nametrastuzumab biobetter (ViroMed/Reyon/Eureka)
Drug Alias NameVM-505
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHelixmith Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEureka Therapeutics IncHelixmith Co LtdReyon Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A